Prescription Drug Supply Chain Pricing Transparency Act
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- Senate
- Sponsors
- 2
- Latest action
- Jan 29, 2026
What it does
The bill would require the Comptroller General of the United States to conduct a study and submit a report to Congress on price-related compensation and payment structures within the prescription drug supply chain, including entities such as pharmacy benefit managers, drug wholesalers, pharmacies, manufacturers, and related service providers. The study would examine the type, prevalence, business models, conflicts of interest, and trends in compensation tied to drug prices, with a report due within two years of enactment. The goal is to increase transparency about how financial incentives tied to drug pricing may influence formulary decisions, distribution, and purchasing across the supply…
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
Where it goes next
While a bill can still move, the questions are about people and money.